close
Upadacitinib 30 mg and Abrocitinib 200 mg were more effective than Dupilumab for reducing EASI scores.
Upadacitinib 15 mg is similar to Dupilumab in terms of reduction in EASI scores
Tralokinumab, Baricitinib, and Abrocitinib 100 mg were less effective
文章標籤
全站熱搜
留言列表
